DSGN logo

Design Therapeutics, Inc.

DSGN
Healthcare|Biotechnology|US
$10.21
+0.54 (+5.58%)
DCF Value
$0.26
Tangible Book / Share
$3.21
Cash / Share
$3.31
Next Earnings Report
Mar 8, 2027
EPS est. -$0.38
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Nov 4, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (11)

Nov 2026
Est. completion
P2P3Small Cell Lung Cancer
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
NCT01064466n=600
Nov 2026
Est. completion
P2P3Prostate Cancer
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
NCT03348670n=600
Nov 2026
Est. completion
P2P3ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
NCT05987956n=600
Nov 2026
Est. completion
Early P1Covid19
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
NCT03305341n=20
Nov 2026
Est. completion
P1Rectal Cancer
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
NCT02403505n=20
Dec 2026
Est. completion
P1P2Friedreich Ataxia
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
NCT06874010n=20
Dec 2026
Est. completion
P2P3Breast Cancer
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
NCT06062810n=600
Dec 2026
Est. completion
P2P3SCLC
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
NCT07145333n=600
Jun 2027
Est. completion
Early P1HIV Infections
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
NCT07182838n=20
Dec 2027
Est. completion
P2Fuchs Endothelial Corneal Dystrophy
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693n=70
Apr 2028
Est. completion
P1P2Cleft Lip and Palate
Phase I-IIa, to Evaluate the Safety, Feasibility, and Efficacy of the Use of BIOCLEFT in the Treatment of Cleft Palate.
NCT06408337n=15

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
Early P1
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563
Oct 2026
P2P3
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
NCT07033585
Jan 2021
NA
CAMH PARTNERs Integrated Care Study
NCT02345122

Recent Press Releases

Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
Nov 4, 2026 · GlobeNewsWire
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Sep 2, 2026 · GlobeNewsWire

SEC Filings (47)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 2026S-3Shelf registrationDocumentIndex
Nov 4, 2026424B5Offering prospectusDocumentIndex
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 3, 202610-QQuarterly reportDocumentIndex
Aug 3, 20268-KMaterial eventDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 18, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 28, 202610-QQuarterly reportDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Apr 23, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 23, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 23, 2026ARSAnnual report to holdersDocumentIndex
Apr 1, 20268-KMaterial eventDocumentIndex
Mar 11, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 9, 2026S-8Employee stock planDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Mar 9, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 30, 20268-KMaterial eventDocumentIndex
Nov 18, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 12, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Sep 10, 20258-KMaterial eventDocumentIndex
Aug 28, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 7, 202510-QQuarterly reportDocumentIndex
Aug 7, 20258-KMaterial eventDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
May 16, 2025EFFECTDocumentIndex
May 7, 2025S-3Shelf registrationDocumentIndex
May 7, 202510-QQuarterly reportDocumentIndex
May 7, 20258-KMaterial eventDocumentIndex
Apr 30, 2025DEFR14ADocumentIndex
Apr 24, 2025ARSAnnual report to holdersDocumentIndex
Apr 24, 2025DEFA14AProxy / shareholder voteDocumentIndex